Storage reference
Peptide storage guide
Rules of thumb for lyophilized vs reconstituted peptides — refrigeration, freezing, shipping, and light exposure. Individual peptide pages have the full detail.
🧊
Lyophilized (dry)
Refrigerate at 2–8 °C for long-term storage. Most peptides tolerate short room-temp exposure during shipping. Freezer (−20 °C) fine for years.
💧
Reconstituted (liquid)
Always refrigerated (2–8 °C). Do NOT freeze once reconstituted — freeze/thaw destroys peptide structure.
☀️
Light & shaking
Protect from light. Swirl gently against the vial wall — never shake vigorously. Foaming denatures peptides.
| Peptide | Lyophilized | Reconstituted | Shipping | Notes | |
|---|---|---|---|---|---|
| 5-Amino-1MQ | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for 5-Amino-1MQ was located. Note that PubChem CID 950107 is the free cation; material is normally handled as a salt (e.g. iodide), whose formula and mass differ from the cation values above. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Acein | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| AHK-Cu | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for AHK-Cu was located in a primary or regulatory source. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Amycretin | No compound-specific data documented | No compound-specific data documented | — | Amycretin is an unapproved investigational product; no public label, SmPC or stability study exists. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| AOD-9604 | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for AOD-9604 was located in a primary or regulatory source. The molecule does contain a disulfide bond (verified from the PubChem structure), which is a chemically relevant feature, but no measured data on freeze-thaw, reduction or reconstituted shelf-life was found. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Apelin | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for apelin peptides was located in a primary or regulatory source. Apelin-13 contains a methionine (a chemically oxidation-prone residue, verified from the PubChem formula/structure) and has an extremely short circulating half-life in humans, but neither observation is a substitute for a measured storage stability figure. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| ARA-290 | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for ARA-290/cibinetide was located in a primary or regulatory source; it has never been marketed, so no SmPC or label exists. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Argireline | No compound-specific data documented | No compound-specific data documented | — | No stability/storage study for argireline as a raw material was located in a primary or regulatory source. It contains a methionine residue (verified from the formula/structure), which is chemically oxidation-prone, but no measured stability figures were found. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| BPC-157 | Room temperature ≤ 30 days, refrigerated (2–8 °C) up to 24 months | Refrigerated (2–8 °C), use within 30 days | Cold-chain preferred; short room-temp exposure tolerated for lyophilized | Protect from light. Do not freeze reconstituted solution. | View → |
| BPC-157 Arginate | No compound-specific data documented | No compound-specific data documented | — | No published stability or storage data exists for the arginate salt specifically. The claim that arginate salt formation improves stability over the free peptide was not found in any peer-reviewed source. The general BPC-157 finding applies: the 2026 Pharmaceutics review states no formal stability, excipient compatibility or reconstitution studies have been done for BPC-157 in any salt form. | View → |
| Cagrilintide | No compound-specific data documented | No compound-specific data documented | — | Cagrilintide is an unapproved investigational product; no public label, SmPC or published stability study exists. It does contain a Cys2-Cys7 disulfide (verified from the PubChem structure), which is chemically relevant, but no measured storage or freeze-thaw data was found. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| CAQK | No compound-specific data documented | No compound-specific data documented | — | No stability or storage study for CAQK was located. Note that the N-terminal free cysteine thiol is chemically oxidation-prone (it is exploited for conjugation in the cited papers), but no measured stability figures are published. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Carnosine | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability or storage study was located. Carnosine is supplied as a crystalline solid and is used orally as a dietary supplement, not as a reconstituted injectable, so lyophilised/reconstituted stability framing does not apply in the way it does to injectable peptides. No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. | View → |
| Cerebrolysin | No compound-specific data documented | No compound-specific data documented | — | Cerebrolysin is a nationally registered medicine in several countries but is not licensed in the UK, EU-centrally or the US, and no publicly accessible SmPC was retrievable in this pass, so no storage temperature or duration is recorded here. It is supplied as a ready-to-use solution in ampoules, not as a lyophilised powder, so lyophilised-stability framing does not apply. | View → |
| CJC-1295 (No DAC) | Refrigerated 24 months | Refrigerated, use within 14–21 days | — | — | View → |
| CJC-1295 (with DAC) | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data could be retrieved from any regulatory label, pharmacopoeia or peer-reviewed stability study. CJC-1295 has no marketing authorisation anywhere, so no approved-product storage specification exists. Only generic lyophilised-peptide handling guidance exists, and no source was found that states specific temperatures or durations for this compound. | View → |
| Cortagen | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label, pharmacopoeia or published stability study that could be retrieved. Cortagen has no marketing authorisation, so no approved-product storage specification exists. Only generic lyophilised-peptide handling guidance would apply. | View → |
| Degarelix | Store the FIRMAGON kit at 20 C to 25 C (68 F to 77 F); excursions permitted to 15 C to 30 C (59 F to 86 F) [USP Controlled Room Temperature]. Refrigeration is NOT required and is not specified. | Reconstituted drug must be administered within one hour after addition of Sterile Water for Injection, USP. No longer-term reconstituted storage is permitted by the label. | — | Do not shake the vials during reconstitution (the label instructs gentle swirling only, and explicitly 'Do not shake the vials'). Supplied as a white to off-white lyophilised powder of degarelix acetate with mannitol (150 mg per 120 mg dose; 200 mg per 80 mg dose). The label gives no photostability statement, so lightSensitive is left null rather than guessed. | View → |
| Dihexa | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label or published stability study that could be retrieved. Dihexa has no marketing authorisation. Only generic handling guidance for a small lipophilic peptidomimetic would apply, and no source was found stating specific temperatures or durations. | View → |
| DSIP | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label, pharmacopoeia or published stability study that could be retrieved. DSIP has no marketing authorisation. Only generic lyophilised-peptide handling guidance would apply. | View → |
| Ecnoglutide | No compound-specific data documented | No compound-specific data documented | — | Ecnoglutide is approved in China only; the NMPA-approved Chinese prescribing information was not retrievable, and no FDA or EMA label exists. No compound-specific storage specification could therefore be verified. It is supplied as a solution for subcutaneous injection rather than a lyophilised research vial. | View → |
| Eloralintide | No compound-specific data documented | No compound-specific data documented | — | Investigational product with no approved label anywhere; no storage specification is public. No compound-specific storage data could be verified. Store lyophilised powder cool and dark; once reconstituted keep refrigerated 2 to 8 C and use within a few weeks | View → |
| Epitalon | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label, pharmacopoeia or published stability study that could be retrieved. Epitalon has no marketing authorisation. Only generic lyophilised-peptide handling guidance would apply. | View → |
| Epithalon | Refrigerated 24 months | Refrigerated, use within 30 days | — | — | View → |
| Exenatide | Not applicable - BYETTA is supplied as a sterile, preserved isotonic solution in a prefilled pen, not as a lyophilised powder. | Store BYETTA in the refrigerator at 36 F to 46 F (2 C to 8 C). After first use, BYETTA can be kept at a temperature not to exceed 77 F (25 C). Discard the pen 30 days after first use, even if some drug remains in the pen. | — | FDA label section 16.2 Storage and Handling states verbatim: 'Do not freeze. Do not use BYETTA if it has been frozen.' and 'Protect BYETTA from light.' The in-use pen may be stored between 2 C and 25 C. Freeze-thaw is explicitly not tolerated. | View → |
| Follistatin 344 | No compound-specific data documented | No compound-specific data documented | — | No approved follistatin product exists, so no regulatory storage specification exists. No published stability study for a follistatin 344 preparation could be retrieved. Note also that Reichel 2019 found that only 9 of 17 tested black-market 'follistatin 344' products actually contained follistatin, so vendor storage claims describe products of unverified content. | View → |
| FOXO4-DRI | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label or published stability study that could be retrieved. FOXO4-DRI has no marketing authorisation. Only generic lyophilised-peptide handling guidance would apply. (D-amino-acid peptides are generally more protease-resistant than L-peptides, but no source giving specific temperatures or durations for this compound was found.) | View → |
| GHK-Cu | No compound-specific data documented | In a published preformulation study, GHK-Cu was stable in water and in buffers across pH 4.5-7.4 for at least two weeks at 60 C. It degraded with first-order kinetics under basic and oxidative stress, and to a lesser extent under acidic stress; three degradation products were identified by HPLC-MS, one of which was free histidine. | — | This is genuine compound-specific stability data from a peer-reviewed preformulation study (Badenhorst 2016, PMID 25384620), not vendor guidance. It also found GHK-Cu compatible with Span 60 based niosomes but less stable in the presence of the negatively charged lipid dicetyl phosphate. No photostability data was found, so lightSensitive is left null. No lyophilised-powder shelf-life study was found. Practical implication: avoid alkaline and oxidising vehicles. | View → |
| GHRP-2 | No compound-specific data documented | No compound-specific data documented | — | GHRP-2 is used as a diagnostic agent in Japan, but the Japanese product labelling could not be retrieved, and there is no FDA or EMA label. No compound-specific storage specification could be verified from an authoritative source. Only generic lyophilised-peptide handling guidance would otherwise apply. | View → |
| GHRP-6 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage data exists in any regulatory label, pharmacopoeia or published stability study that could be retrieved. GHRP-6 has no marketing authorisation. Only generic lyophilised-peptide handling guidance would apply. | View → |
| Glutathione | No compound-specific data documented | No compound-specific data documented | — | No compound-specific storage specification could be verified from an authoritative source. PubChem holds no Storage Conditions or Stability/Shelf Life section for CID 124886, and there is no FDA- or EMA-approved reduced-glutathione drug product whose label could be cited. The chemically relevant caution - that the free cysteine thiol oxidises to the disulfide GSSG - follows from the structure, but no source giving specific temperatures, durations or a photostability statement was retrieved, so all storage fields are left null rather than guessed. | View → |
| Gonadorelin | No compound-specific data documented | No compound-specific data documented | — | No human gonadorelin product is currently marketed in the US, so no current human prescribing information states storage requirements. The historic human products (Factrel, NDA 018123; Lutrepulse Kit, NDA 019687) are both listed as Discontinued in Drugs@FDA and their labels are no longer in DailyMed. The only gonadorelin labels currently in DailyMed are veterinary aqueous solutions; the Fertagyl (Merck Animal Health) label states: 'Keep refrigerated: 2-8 C (36-46 F). 20-mL vial: Use within 28 days of first puncture.' That figure applies to that veterinary solution formulation only and is not a human-product specification. No light-sensitivity or freeze-thaw statement was found in any gonadorelin label retrieved. | View → |
| GV1001 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. GV1001 has no marketing authorisation, so no approved-product storage specification exists. | View → |
| Hexarelin | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. Hexarelin was never marketed, so no approved-product storage specification exists. | View → |
| Humanin | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. Humanin has no approved product and no pharmacopoeial monograph. | View → |
| IGF-1 LR3 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. LR3-IGF-I is a research reagent protein with no approved product. Kohler et al. 2010 (PMID 20675162) further found that a black-market 'IGF-1 LR3' injection vial actually contained His-tagged Long-R3-IGF-I, a biochemical research construct, so material sold under this name is not of a defined pharmaceutical quality. | View → |
| Ipamorelin | Refrigerated 24+ months | Refrigerated, use within 30 days | — | — | View → |
| Kisspeptin | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. Kisspeptin has no approved product in any jurisdiction. | View → |
| Klotho | No compound-specific data documented | No compound-specific data documented | — | Not applicable in the usual sense. Klotho is a large glycosylated protein with no approved or investigational human drug product, so no storage specification exists anywhere in regulatory or pharmacopoeial sources. Any storage guidance circulating for 'Klotho' refers to research-grade recombinant protein preparations from individual suppliers, which are lot- and supplier-specific and are not a property of the compound. | View → |
| KPV | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. KPV has no approved product and no pharmacopoeial monograph. | View → |
| Liraglutide | Not applicable - liraglutide is not supplied lyophilised. Saxenda is a 6 mg/mL solution in a prefilled pen. Per the FDA label: 'Prior to first use, SAXENDA should be stored in a refrigerator between 36F to 46F (2C to 8C). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze SAXENDA and do not use SAXENDA if it has been frozen.' | In-use (after first use of the pen): 'the pen can be stored for 30 days at controlled room temperature 59F to 86F (15C to 30C) or in a refrigerator 36F to 46F (2C to 8C). Keep the pen cap on when not in use.' | — | Freeze-thaw: not tolerated. The label instructs not to freeze and not to use product that has been frozen. Figures above are from the US Saxenda (liraglutide 3.0 mg) prescribing information, section 16 How Supplied/Storage and Handling. | View → |
| Livagen | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. Livagen has no approved product; the published work is Russian-language laboratory and ex vivo research. | View → |
| LL-37 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific published stability data (temperature/duration for lyophilised or reconstituted material, light sensitivity, freeze-thaw tolerance) was located in any regulatory label, pharmacopoeial monograph or peer-reviewed source. Only generic lyophilised-peptide handling guidance exists, and generic guidance is not compound-specific; no specific figures are asserted here. LL-37 has no approved product. The clinical development compound (ropocamptide) was a topical formulation given at 0.5, 1.6 and 3.2 mg/mL, but the published trial reports do not state storage or stability conditions. | View → |
| Macimorelin | Supplied as white to off-white granules in a single-dose aluminium pouch (60 mg macimorelin, equivalent to 68 mg macimorelin acetate). Per the Macrilen FDA label section 16: 'Store pouches under refrigeration at 2-8C (36-46F).' | 'The solution must be used within 30 minutes after preparation. Discard unused portion.' This is a hard 30-minute in-use limit, not a multi-day one. | — | No light-sensitivity or freeze-thaw statement appears in the Macrilen prescribing information; those fields are left null rather than guessed. Reconstitution must be performed by a healthcare professional per the label. | View → |
| MariTide | No compound-specific data documented | No compound-specific data documented | — | MariTide is investigational and has no approved label, so no public storage specification exists. No compound-specific stability data was located in any regulatory or peer-reviewed source. | View → |
| Mazdutide | No compound-specific data documented | No compound-specific data documented | — | Mazdutide is approved only in China (Xinermei). No English-language prescribing information was retrievable, and no storage specification is present in FDA, EMA or DailyMed sources. No storage figures are asserted here. | View → |
| Melanotan I | No compound-specific data documented | No compound-specific data documented | — | No published stability data for lyophilised or reconstituted research-grade Melanotan I powder was located. The only compound-specific storage instruction that could be sourced is for the approved product SCENESSE (afamelanotide 16 mg subcutaneous implant): 'Store in a refrigerator at 2 degrees C - 8 degrees C (36 F-46 F). Protect from light.' That instruction applies to a solid implant, not to a reconstituted solution, and should not be read across to vialled powder. | View → |
| Melanotan II | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to Melanotan II was located. There is no approved product and therefore no label storage section. Any temperature/duration figures circulating for this compound come from vendor material, which is not an acceptable source. Only generic lyophilised-peptide handling guidance exists. | View → |
| MGF | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to MGF was located. There is no approved product and no label. Only generic lyophilised-peptide handling guidance exists. | View → |
| MK-677 | No compound-specific data documented | No compound-specific data documented | — | Not a lyophilised peptide; storage fields modelled on peptide handling do not apply. No approved product exists, so there is no label storage section, and no peer-reviewed stability data for MK-677 was located. | View → |
| MOTS-c | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to MOTS-c was located. There is no approved product and no label. Only generic lyophilised-peptide handling guidance exists. Note the sequence contains two methionine residues, which are oxidation-prone in solution, but no published study quantifying this for MOTS-c was found. | View → |
| N-Acetyl Selank | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to N-Acetyl Selank, or to Selank, was located. Only generic lyophilised-peptide handling guidance exists. | View → |
| N-Acetyl Semax | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to N-Acetyl Semax, or to Semax, was located. Only generic lyophilised-peptide handling guidance exists. | View → |
| NAD+ | No compound-specific data documented | No compound-specific data documented | — | No regulatory label or peer-reviewed stability study specific to pharmaceutical NAD+ preparations was located. NAD+ is a laboratory reagent as well as an infusion ingredient and reagent-supplier storage advice is not an acceptable source for this dataset. Peptide-style lyophilised/reconstituted stability fields are in any case a poor fit for a coenzyme. | View → |
| Neuropeptide Y | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to NPY was located. There is no approved product and no label. Only generic lyophilised-peptide handling guidance exists. | View → |
| Oxytocin | No compound-specific data documented | No compound-specific data documented | — | The approved US product (Pitocin, oxytocin injection USP, 10 units/mL) is supplied as a ready-to-use solution, not a lyophilised powder, and its label instructs: 'Store between 20 degrees to 25 degrees C (68 degrees to 77 degrees F).' No lyophilised or reconstituted stability data applies to the approved product, and no light-protection instruction appears in the retrieved label section. | View → |
| P21 | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to P021 was located. There is no approved product and no label. Only generic peptide handling guidance exists. | View → |
| Palmitoyl Pentapeptide-4 | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data for the raw ingredient was located. As a cosmetic ingredient it is supplied already formulated into finished products, whose storage is governed by the finished-product manufacturer, not by peptide-vial conventions. Lyophilised/reconstituted stability fields do not meaningfully apply. | View → |
| PE-22-28 | No compound-specific data documented | No compound-specific data documented | — | No peer-reviewed or regulatory stability data specific to PE-22-28 was located. The published work characterises IN VIVO plasma stability (duration of action up to 23 hours in mice versus about 7 hours for spadin), which is a pharmacokinetic property and not a storage instruction; it must not be presented as shelf life. | View → |
| PEG-MGF | No compound-specific data documented | No compound-specific data documented | — | No data of any kind was located. | View → |
| Peginesatide | No compound-specific data documented | No compound-specific data documented | — | The approved product OMONTYS was a ready-to-use solution, not a lyophilised powder. Label: 'The recommended storage temperature is refrigerated at 2 degrees C to 8 degrees C (36 F to 46 F). Protect from light. Retain in carton until time of use.' Where refrigeration was unavailable, vials and prefilled syringes could be held at 25 degrees C or less for up to 30 days. Multiple-use vials were to be returned to 2-8 degrees C after first use and discarded after 28 days. Single-use vials and prefilled syringes were for one use only. | View → |
| Pemvidutide | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Pemvidutide is investigational and has no approved label. | View → |
| Pentosan Polysulfate | No compound-specific data documented | No compound-specific data documented | — | Marketed as ELMIRON 100 mg oral gelatin-coated capsules; there is no lyophilised or reconstituted presentation. Label storage: 'Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F).' No light-protection or freeze-thaw instruction is given. The bulk drug substance is described in the label as a white odourless powder that is slightly hygroscopic and soluble in water to 50% at pH 6. | View → |
| Pinealon | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Pinealon has no approved label anywhere that could be located. | View → |
| PT-141 | No compound-specific data documented | Not applicable — VYLEESI is supplied as a ready-to-use single-dose autoinjector. | — | VYLEESI label, Storage and Handling: 'Store at or below 25 °C (77 °F). Do not freeze. Protect from light.' No refrigeration is required and no lyophilised presentation is marketed. | View → |
| Retatrutide | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Retatrutide is investigational and has no approved label. | View → |
| RGTA OTR4120 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. OTR4120 is a polymer supplied in commercial topical/ophthalmic presentations; no storage specification from a regulatory document was located. | View → |
| Selank | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Selank has no FDA or EMA label; no peer-reviewed stability study was located. | View → |
| Semaglutide | Refrigerated 24 months | Refrigerated, use within 56 days (clinical labeling reference) | — | Do not freeze once reconstituted. | View → |
| Semax | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Semax has no FDA or EMA label; no peer-reviewed stability study was located. | View → |
| Sermorelin | No compound-specific data documented | No compound-specific data documented | — | Sermorelin has no currently marketed FDA-labelled product. Both Geref approvals (NDA 019863 and NDA 020443, EMD Serono) are recorded as Discontinued in Drugs@FDA, and no active prescribing information with storage or in-use stability data could be retrieved. No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Storage figures circulating on compounding-pharmacy and peptide-vendor pages are not acceptable sources and are not recorded. | View → |
| Setmelanotide | Not applicable — IMCIVREE is supplied as a solution in multiple-dose vials, not lyophilised. Unopened vials are stored refrigerated at 2-8 degC (36-46 degF); they may be kept at room temperature for up to 30 days before the expiration date. | After the vial is punctured (opened), discard after 30 days. | — | No light-protection requirement is stated in the IMCIVREE prescribing information, and no freeze-thaw tolerance is claimed. | View → |
| Snap-8 | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Snap-8 is a cosmetic ingredient rather than a drug and has no regulatory label carrying stability data. | View → |
| SS-31 | Not applicable — FORZINITY is supplied as a solution in single-patient-use vials (280 mg/3.5 mL, 80 mg/mL), not lyophilised. Store refrigerated at 2-8 degC (36-46 degF). Do not freeze. | Following the first dose, the opened vial can be stored either refrigerated at 2-8 degC or at room temperature 20-25 degC (68-77 degF). Discard vials 8 days after first opening. | — | No light-protection instruction appears in the FORZINITY prescribing information. Do not freeze. | View → |
| Survodutide | No compound-specific data documented | No compound-specific data documented | — | No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Survodutide is investigational and has no approved label. | View → |
| TB-500 | Refrigerated (2–8 °C), stable ~24 months | Refrigerated, use within 30 days | — | — | View → |
| Tesamorelin | EGRIFTA WR 11.6 mg vial: 'Store EGRIFTA WR 11.6 mg vial at room temperature at 20 C to 25 C (68 F to 77 F).' EGRIFTA SV 2 mg vial: 'Store at room temperature at 20 C to 25 C (68 F to 77 F); excursions permitted to 15 C to 30 C (59 F to 86 F).' Neither approved presentation is stored frozen. | EGRIFTA WR (reconstituted with Bacteriostatic Water): 'Discard unused solution of EGRIFTA WR vial 7 days after mixing'; stored at room temperature; 'Do not freeze.' EGRIFTA SV (reconstituted with Sterile Water): administer immediately; 'If not used immediately, discard the reconstituted solution. Do not freeze or refrigerate the reconstituted solution.' | — | EGRIFTA SV label: 'Protect EGRIFTA SV from light by keeping in the original box until time of use.' The two currently marketed presentations differ materially in diluent and in-use stability, so a single storage line cannot cover both. No freeze-thaw tolerance data appear in either label. | View → |
| Tesofensine | No compound-specific data documented | No compound-specific data documented | — | No approved product label exists anywhere, so there is no authoritative storage specification. Tesofensine is an orally dosed small molecule (tablet/capsule in trials), not a lyophilised peptide, so lyophilised/reconstituted storage categories do not apply. No compound-specific stability data located from a citable regulatory or peer-reviewed source. | View → |
| Thymalin | No compound-specific data documented | No compound-specific data documented | — | No FDA or EMA label exists (absent from Drugs@FDA and DailyMed). Thymalin is a Russian-registered immunomodulatory preparation; its Russian package insert was not retrievable from a source acceptable under this project's rules, and no peer-reviewed stability data were located. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| Thymopentin | No compound-specific data documented | No compound-specific data documented | — | No current FDA or EMA label exists (absent from Drugs@FDA and DailyMed), so no authoritative storage specification could be retrieved. The historical European product Timunox (Cilag) is no longer accessible as a label. No compound-specific stability data located in indexed literature. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| Thymosin Alpha-1 | ZADAXIN label: store the lyophilised vial 'between 2 and 8 C (36 and 46 F)' - refrigerated, not frozen. | ZADAXIN label: 'It should be used immediately after reconstitution.' No hold time is authorised. | — | Storage taken from the ZADAXIN (thymalfasin) 1.6 mg package insert as filed with the Indonesian regulator BPOM. The label gives no light-protection statement and no freeze-thaw data, so those remain unknown. This directly contradicts the ported '-20 C / 4 weeks reconstituted' boilerplate. | View → |
| Thymosin Beta-4 | No compound-specific data documented | No compound-specific data documented | — | No approved product exists in any jurisdiction, so there is no authoritative storage specification. The clinical material studied (RGN-259) is a 0.1% ophthalmic solution, not a reconstituted injectable, and its storage conditions are not published in the trial reports located. No compound-specific stability data found. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| Thymulin | No compound-specific data documented | No compound-specific data documented | — | No approved medicinal product exists (the only DailyMed entry for the name is an unapproved homeopathic pellet, 'THYMULINE (NONATHYMULIN) PELLET', which is not a source for peptide handling). No compound-specific stability data located in indexed literature. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| Tirzepatide | Not applicable - tirzepatide is supplied as a ready-to-use sterile solution, not a lyophilised powder. Label: 'Store ZEPBOUND single-dose pen and single-dose vial in a refrigerator at 2 C to 8 C (36 F to 46 F).' | No reconstitution step. In-use limits from the label: single-dose pen or vial may be stored unrefrigerated at up to 30 C for a total of 21 days, then discarded. Unopened multi-dose vial or KwikPen: refrigerated until expiry, or 30 days if kept at room temperature. Opened multi-dose vial or KwikPen: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first. | — | Label verbatim: 'Do not freeze ZEPBOUND. Do not use ZEPBOUND if frozen. Protect ZEPBOUND from heat and light. Store ZEPBOUND in the original carton to protect from light.' Freezing is an absolute disqualifier - there is no freeze-thaw tolerance. | View → |
| Vesugen | No compound-specific data documented | No compound-specific data documented | — | No approved product and no regulatory label anywhere; no compound-specific stability data in any indexed publication. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| Vilon | No compound-specific data documented | No compound-specific data documented | — | No approved product and no regulatory label anywhere; no compound-specific stability data in any indexed publication. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| VIP | No compound-specific data documented | No compound-specific data documented | — | No approved product label could be retrieved. Aviptadil has no FDA approval (absent from Drugs@FDA and DailyMed) and a UK emc search for aviptadil returns no licensed medicine. No compound-specific stability data located in indexed literature. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. | View → |
| VK2735 | No compound-specific data documented | No compound-specific data documented | — | Investigational product with no approved label; storage conditions are not disclosed in the trial registrations or the phase 2 publication. No data. | View → |
✅ Do
- ✓Keep a dedicated peptide shelf in the fridge — away from food.
- ✓Label reconstituted vials with the date and concentration.
- ✓Use BAC water (0.9% benzyl alcohol) for anything you'll use more than once.
- ✓Wipe the stopper with a fresh alcohol swab every draw.
✕ Don't
- ✕Freeze reconstituted peptides.
- ✕Store on the fridge door — temperature swings degrade peptides.
- ✕Leave vials in direct sunlight or on a warm windowsill.
- ✕Reuse a syringe or needle between vials.